PenderFund Capital Management’s Maravai LifeSciences MRVI Stock Holding History

PenderFund Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$580K	Sell	205,000 -15,500	-7%	-$52.5K	0.09%	70
2025 Q4	$717K	Sell	220,500 -199,357	-47%	-$671K	0.11%	55
2025 Q3	$1.2M	Sell	419,857 -450,343	-52%	-$1.15M	0.2%	46
2025 Q2	$2.1M	Buy	870,200 +43,900	+5%	+$92.3K	0.5%	37
2025 Q1	$1.49M	Buy	826,300 +246,000	+42%	+$972K	0.41%	39
2024 Q4	$4.55M	Buy	+580,300	New	+$3.73M	0.98%	20
2022 Q4	–	Sell	-1,200	Closed	-$42K	–	142
2022 Q3	$42K	Hold	1,200	–	–	0.01%	162
2022 Q2	$44K	Buy	+1,200	New	+$38K	0.01%	152

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PenderFund Capital Management's MRVI Position: Q1 2026 in Review

PenderFund Capital Management reduced its Maravai LifeSciences (MRVI) stake by 7% in Q1 2026, selling an estimated $52.5K and leaving 205,000 shares worth $580K. The position accounts for 0.09% of the portfolio, ranked #70.

PenderFund Capital Management first reported a position in MRVI in Q2 2022 and has held it in 8 quarters since. The position peaked at $4.55M in Q4 2024. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

PenderFund Capital Management held 205,000 shares of Maravai LifeSciences worth $580K as of Q1 2026.
PenderFund Capital Management sold 15,500 Maravai LifeSciences shares in Q1 2026, an estimated $52.5K.
Maravai LifeSciences made up 0.09% of PenderFund Capital Management's portfolio in Q1 2026, its #70 holding.
PenderFund Capital Management first reported a position in Maravai LifeSciences in Q2 2022 and has held it in 8 quarters since.
PenderFund Capital Management's Maravai LifeSciences position peaked at $4.55M in Q4 2024.
158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on PenderFund Capital Management's 13F filing for Q1 2026, filed 15 May 2026.